Core Viewpoint - BioAtla, Inc. is exploring strategic options to maximize shareholder value, including potential asset sales and partnerships, while implementing a significant restructuring plan to reduce operating expenses by approximately 70% [1][2]. Company Overview - BioAtla is a clinical-stage biotechnology company based in San Diego, focusing on Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [3]. - The company utilizes a proprietary CAB platform technology to develop novel monoclonal and bispecific antibodies, aiming for selective targeting and reduced toxicity compared to traditional antibodies [3]. - BioAtla holds over 780 active patent matters, with more than 500 issued patents, covering methods of making and manufacturing CAB product candidates [3]. Clinical Pipeline - BioAtla's clinical pipeline includes several assets at various stages: - Ozuriftamab vedotin (CAB-ROR2-ADC) is in Phase 3 for treating oropharyngeal squamous cell carcinoma (OPSCC) and has potential applications in HPV+ cancers, representing a market opportunity of over $7 billion [8]. - Mecbotamab vedotin (CAB-AXL-ADC) is in Phase 2 for multiple solid tumor indications, including mKRAS NSCLC and soft tissue sarcoma [10]. - Evalstotug (CAB-CTLA-4) is in Phase 2, designed for safer combination therapies with anti-PD-1 agents [11]. - BA3182 (CAB-EpCAM x CAB-CD3) is in Phase 1 for advanced adenocarcinoma [7]. Strategic Actions - The company has engaged Tungsten Advisors as its exclusive strategic financial advisor to assist in evaluating potential transactions [2]. - The restructuring plan aims to retain essential employees while significantly reducing the workforce to enhance cost containment [1].

Core Insights - Wrap Technologies, Inc. has launched a Florida-based integrated drone testing and non-lethal response training headquarters through a strategic partnership with WOFT, LLC, aimed at addressing military, federal, and civilian interests in non-lethal technologies [1][3][12] Group 1: Facility Overview - The Florida facility will serve as an operational hub for counter-UAS validation, drone-enabled non-lethal deployment testing, and training programs for federal, state, and local agencies [2][4] - The site is designed to integrate engineering validation, operational simulation, and certification-based training into a scalable environment supporting Wrap's drone-enabled non-lethal response ecosystem [4][5] Group 2: Testing and Training Initiatives - The facility will host controlled evaluation programs simulating real-world security environments, which will support product refinement and accelerate agency procurement decisions [5][6] - It will also facilitate structured drone-to-human deployment scenarios to evaluate aerial platforms' effectiveness in dynamic encounters while maintaining lawful authority [6][10] Group 3: Training Programs and Certification - The site is intended to be a recurring training destination for agencies implementing Wrap's non-lethal response doctrine, emphasizing stress-based decision-making and scenario immersion [7][11] - Planned programs include instructor certification courses and scenario-based implementation laboratories to enhance operational readiness [11][12] Group 4: Strategic Partnership and Market Positioning - The partnership designates Wrap as the lead partner for integrated solution determinations, providing exclusivity protections from certain competitors [13][14] - By consolidating training, testing, and validation into one operational environment, Wrap aims to accelerate the adoption of non-lethal and counter-drone technologies [12][16] Group 5: Long-term Vision - Wrap's long-term vision is to establish non-lethal technology as a foundational layer of lawful proactive response, integrating aerial systems and human response doctrine [15][16] - The facility is expected to begin hosting scheduled agency training programs and validation events in Q2 2026, marking a significant step toward unifying various operational capabilities [16]

Core Viewpoint - The U.S. FDA has lifted the clinical hold on Intellia Therapeutics' Investigational New Drug application for the MAGNITUDE Phase 3 trial of nexiguran ziclumeran (nex-z) for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM) [1][2] Group 1: Clinical Trials - The MAGNITUDE trial is a randomized, double-blind, placebo-controlled study involving approximately 1,200 patients with ATTR-CM, focusing on cardiovascular-related events as the primary endpoint [3] - The MAGNITUDE-2 trial is also a randomized, double-blind, placebo-controlled study, but it targets around 60 patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN), with primary endpoints including changes in neuropathy impairment scores and serum TTR levels [4] Group 2: Safety Measures and FDA Collaboration - The FDA had previously imposed clinical holds on both MAGNITUDE and MAGNITUDE-2 trials due to safety concerns, specifically elevated liver transaminases and bilirubin levels in a patient [2] - Intellia has collaborated with the FDA to implement enhanced safety measures, including increased monitoring of liver tests and exclusion criteria for patients with certain liver abnormalities and cardiovascular instability [2] Group 3: Product Information - Nex-z is based on CRISPR/Cas9 gene editing technology and aims to be the first one-time treatment for ATTR-CM and hereditary ATTR with polyneuropathy [5] - Interim Phase 1 clinical data indicated that nex-z led to significant and lasting reductions in TTR levels, and it has received Orphan Drug and RMAT Designations from the FDA [5] Group 4: Company Overview - Intellia Therapeutics is a clinical-stage biopharmaceutical company focused on leveraging CRISPR gene editing to develop potentially curative treatments for severe diseases [6]

Core Viewpoint - Nexxen International Ltd. has announced a share repurchase of 496,981 shares at an average price of $6.02, with a remaining authorization of approximately $2.0 million under its current program [1][2]. Group 1: Share Repurchase Program - The company repurchased 496,981 shares in February 2026 at an average price of $6.02 [1]. - As of February 28, 2026, Nexxen had 55,720,779 ordinary shares outstanding, excluding treasury shares [1]. - Nexxen has received authorization for a new share repurchase program of up to $40 million, which will begin after the current program concludes [2]. Group 2: Program Details - The new share repurchase program does not obligate the company to repurchase a specific number of shares and can be suspended or modified at any time [2]. - Shares repurchased under the new program will be classified as dormant shares under Israeli Companies Law and held in treasury without rights [2]. Group 3: Company Overview - Nexxen is a global advertising technology platform specializing in data and advanced TV, offering a flexible technology stack that includes a demand-side platform and a supply-side platform [4]. - The company is headquartered in Israel and has offices in the United States, Canada, Europe, and Asia-Pacific, and is traded on Nasdaq under the ticker NEXN [5].

Core Viewpoint - Winshear Gold Corp. has successfully closed a non-brokered private placement, raising $2,500,000 through the issuance of 25,000,000 Units, each consisting of one common share and one half of a share purchase warrant [1] Group 1: Private Placement Details - The Offering consists of 25,000,000 Units for gross proceeds of $2,500,000, with each full Warrant allowing the purchase of one Share at a price of $0.20 for 36 months [1] - Finder fees totaling $48,375 in cash and 459,000 Warrants were paid to various financial institutions, with the compensation Warrants having the same terms as those issued to subscribers [2] - All securities from this private placement are subject to a hold period expiring on July 3, 2026 [2] Group 2: Use of Proceeds - Proceeds from the Offering will be allocated to fund exploration activities for the Portsoy Project in Scotland and for general working capital [3] - Certain directors and officers of Winshear purchased a total of 2,150,000 Units in the Offering, which is classified as a "related party transaction" but is exempt from certain valuation and shareholder exemption requirements [3] Group 3: Company Overview - Winshear Gold Corp. is a Canadian-based minerals exploration company with projects including a nickel-copper-cobalt project in Scotland (Portsoy Project) and a gold/critical minerals project in Ontario (Thunder Bay Project) [4]

Core Viewpoint - One Bullion Ltd. has approved a consolidation of its common shares at a ratio of one new share for every ten existing shares, effective March 4, 2026 [1][2]. Company Overview - One Bullion Ltd. is a Toronto-based gold exploration company focused on advancing high-quality gold assets in Botswana, controlling approximately 8,004 km² of prospective land across three projects: Vumba, Kraaipan, and Maitengwe [5]. - The company was established in 2018 and emphasizes disciplined, data-driven exploration while committing to environmental stewardship and community engagement [5]. Share Consolidation Details - The consolidation was approved by a director resolution, and shareholders must surrender their existing share certificates to receive new certificates reflecting the post-consolidation shares [2]. - The common shares reflecting the consolidation will begin trading on the TSX Venture Exchange under the same symbol "OBUL" starting March 4, 2026 [2]. Consulting Agreement - In connection with the consolidation, SLD Capital Corp. is entitled to receive 200,000 common shares as per a consulting agreement dated July 8, 2024, subject to a statutory hold period [3]. Restricted Share Units - The company has granted a total of 1,100,000 restricted share units to its officers and directors [4].

Core Viewpoint - Nykredit Realkredit A/S has received approval to redeem its SEK 1,000,000,000 Subordinated Floating Rate Notes on the first Optional Redemption Date, which is set for 31 March 2026, including accrued interest [1]. Group 1 - Nykredit Realkredit A/S has obtained approval from the Danish Financial Supervisory Authority for the redemption of its subordinated notes [1]. - The total amount of the subordinated notes to be redeemed is SEK 1,000,000,000 [1]. - The redemption will occur on 31 March 2026 at the Final Redemption Amount plus accrued interest [1].

Core Viewpoint - Cognition Therapeutics is advancing the development of zervimesine for treating dementia with Lewy bodies (DLB) psychosis, which affects up to 75% of DLB patients, following positive feedback from the FDA [1][2][3] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for age-related neurodegenerative disorders [8] - The company has completed Phase 2 studies of zervimesine in DLB and mild-to-moderate Alzheimer's disease, with ongoing studies supported by significant grants from the National Institute on Aging [8] Drug Development - Zervimesine (CT1812) is an investigational oral medication aimed at treating CNS diseases, including Alzheimer's and DLB, by interrupting the toxic effects of Aβ and ɑ-synuclein [6][7] - The Phase 2 SHIMMER study demonstrated zervimesine's positive impact on neuropsychiatric symptoms, showing an 86% slowing of decline on the neuropsychiatric inventory compared to placebo [5] Regulatory Strategy - The company plans to pursue a registrational path for zervimesine based on the strength of Phase 2 data and FDA meeting minutes, aiming to expedite its market entry [2][3] - Cognition expects to meet with the FDA Division of Psychiatry to discuss the DLB psychosis program by mid-2026 [2] Patient Impact - DLB psychosis significantly burdens patients and caregivers, leading to higher healthcare costs and earlier institutionalization, with no approved medications currently available for this condition [4] - Zervimesine has shown a favorable impact on cognitive fluctuations, memory, movement, and daily living activities without impairing motor skills, addressing a critical need for DLB patients [3]

Core Viewpoint - Palvella Therapeutics, Inc. has successfully closed an upsized public offering, raising $230 million to support the development of its therapies for rare skin diseases and vascular malformations [1][3]. Group 1: Offering Details - The public offering consisted of 1,840,000 shares of common stock, priced at $125.00 per share, including the full exercise of the underwriters' option for an additional 240,000 shares [1]. - The offering was managed by several financial institutions, including TD Cowen, Cantor, and Stifel, among others [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the development of Palvella's product candidates, specifically QTORIN rapamycin and QTORIN pitavastatin, as well as for general corporate purposes including research and development expenses [3]. Group 3: Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases and vascular malformations, with no FDA-approved treatments currently available [6]. - The company's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, targets microcystic lymphatic malformations and other skin conditions, while QTORIN™ pitavastatin is aimed at treating disseminated superficial actinic porokeratosis [6].

Core Viewpoint - Alterity Therapeutics is advancing ATH434 in late-stage clinical development for Multiple System Atrophy (MSA), a rapidly progressive neurodegenerative disease with no approved therapies [1][3] Company Overview - Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly MSA and related Parkinsonian disorders [1][10] - The company is preparing to initiate a Phase 3 pivotal trial in MSA, having demonstrated clinically meaningful efficacy in a Phase 2 clinical trial [10] Disease Background - MSA is characterized by motor impairment, autonomic dysfunction, and rapid loss of independence, with symptoms resembling Parkinson's disease, making early diagnosis challenging [2][9] - The disease affects up to 50,000 individuals in the U.S., and there are currently no approved drugs to slow its progression or cure it [9] Clinical Development of ATH434 - ATH434 is an investigational oral therapy designed to redistribute excess iron in the brain, which contributes to neurodegeneration in MSA [3][6] - Positive results from a randomized, double-blind, placebo-controlled Phase 2 clinical trial showed robust clinical efficacy and a favorable safety profile [6][8] - The Phase 2 trial enrolled 77 adults and demonstrated significant improvement on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I compared to placebo [8] Research and Biomarkers - The clinical program incorporates biomarkers and advanced neuroimaging to better characterize disease progression and assess therapeutic impact [4] - Biomarkers indicated that both dose levels of ATH434 reduced iron accumulation in MSA-affected brain regions and showed trends in preserving brain volume [8] Awareness and Advocacy - Throughout MSA Awareness Month, the company will share educational information and highlight the experiences of the MSA community, emphasizing the need for continued research [5]